Chai Discovery, a biotechnology company using advanced computational models to predict and reprogram biochemical interactions, has raised $70 million in Series A funding. This follows a $30 million seed round closed last year.
The round was led by Menlo Ventures, through its Anthology Fund in partnership with Anthropic, and joined by new backers Yosemite, DST Global Partners, SV Angel, Avenir, DCVC, and others. Existing investors Thrive Capital, OpenAI, Dimension, Neo, Lachy Groom, and Fred Ehrsam also participated.
The company is tackling one of the most complex challenges in modern science: accelerating the creation of life‑changing therapeutics. Its platform applies computational models to simulate how molecules interact at the biochemical level, aiming to drastically shorten the time needed to identify potential drugs.
Experienced founding team
The company was co‑founded in 2024 by Joshua Meier, formerly of AI drug discovery firm Absci, Facebook AI, and OpenAI; Jack Dent, an engineering and product leader from Stripe; and AI researchers Matthew McPartlon and Jacques Boitreaud. Their combined backgrounds span machine learning, structural biology, and large‑scale product development.
Adding further credibility to the scientific direction, Mikael Dolsten, M.D., Ph.D., former Chief Scientific Officer at Pfizer, has joined Chai’s board of directors. During his tenure at Pfizer, Dolsten oversaw the advancement of 150 molecules into clinical trials and the approval of 36 medicines. His guidance is expected to be instrumental as Chai moves from computational design to real‑world therapeutic applications.
From Chai‑1 to Chai‑2: Transformative advances in molecular design
In 2024, Chai released Chai‑1, an open‑source foundation model for molecular structure prediction that quickly established itself as a leader in its category. The model enables precise predictions of molecular shapes and interactions, giving researchers a powerful tool to explore potential drug candidates more efficiently.
Last month, the company unveiled Chai‑2, representing a major leap in computational drug discovery. Chai‑2 enables fully de novo antibody design with a hit rate approaching 20%. This is a stark improvement over traditional lab‑based screening methods, which often require testing millions or even billions of antibodies to find a viable candidate. The previous computational benchmark was around 0.1%, making Chai‑2’s results a dramatic increase in efficiency.
The system requires only a target antigen and epitope as input. From there, it can generate entirely new antibodies capable of binding precisely to the target. This capability allows scientists to design antibodies for a wide range of targets, including those linked to viruses, cancer cells, and other disease‑causing proteins, without relying on existing antibody templates.
Impact on drug development
The implications of this breakthrough are significant. By reducing the scale and cost of laboratory screening, Chai’s approach could make it economically viable to pursue treatments for diseases that have historically been neglected due to their complexity or smaller patient populations. Moreover, the speed at which candidates can be identified may help address urgent public health threats by shortening the timeline from target identification to clinical testing.
Chai’s platform could also open new possibilities in precision medicine. Because it can generate antibodies specifically tuned to unique protein structures, the technology may enable the creation of therapies tailored to individual patient profiles or highly specific disease subtypes.
Next steps and strategic focus
The newly secured Series A funding will be directed toward expanding the Chai platform’s capabilities, particularly in tackling previously inaccessible biological targets. The company also plans to onboard select partners to apply its models in collaborative research programs. By focusing on both platform development and strategic partnerships, Chai aims to build a robust ecosystem around its technology, enabling faster and broader adoption in the biopharmaceutical sector.
As part of its growth strategy, Chai will continue refining its models to improve accuracy and broaden the range of molecules they can design. Given the speed of advancements from Chai‑1 to Chai‑2, further iterations are expected to push the boundaries of computational biology even further.
Positioning in a competitive landscape
Chai’s unique positioning lies in its combination of high‑accuracy molecular predictions, proven de novo antibody generation, and an open‑source foundation that fosters transparency and community involvement. If Chai continues its trajectory, its technology could play a pivotal role in rewriting the timeline for drug discovery, turning years of laboratory work into a matter of months, and bringing new treatments to patients far sooner than current methods allow.
“Progress towards game-changing drugs and treatments is far too slow, stymied by costly trial-and-error experiments,” said Joshua Meier, CEO and co-founder. “Chai Discovery exists to push the boundaries of what’s possible in this field, applying frontier AI to transform biology from science to engineering, so that breakthroughs can be designed rather than simply discovered.”
“I’m proud to join Chai Discovery and redefine biology from science into engineering,” Dr. Dolsten said. “This is going to be an incredible journey with an incredible team.”
“Before Chai-2, the process was not unlike searching a giant bunch of keys for the right fit for a lock—but there are millions of keys,” said Matthew McPartlon, co-founder. “Now, it’s like having a master locksmith design exactly the right shape key, based only on your description of the lock. A company had spent more than three years and over $5m on a problem. With Chai-2, we were able to find an experimentally validated solution within two weeks.“
“Chai is an exceptional technical team building foundation models for biology to transform drug discovery,“ said Greg Yap, Partner at Menlo Ventures. “Chai-2 demonstrates amazing progress in antibody design, and we have seen a meaningful fraction of the biotech industry already apply for Chai-2 access. At Menlo, we invest deeply in both AI foundation models and technology-enabled biology–we believe Chai can help create better medicines faster.”